Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Neuropharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1433030

HLH-30/TFEB Modulates Autophagy to Improve Proteostasis in Aβ Transgenic Caenorhabditis elegans

Provisionally accepted
Hongbing Wang Hongbing Wang 1*Hongru Lin Hongru Lin 1Chen Zhang Chen Zhang 1Yehui Gao Yehui Gao 1Yi Zhou Yi Zhou 2Botian Ma Botian Ma 1Jinyun Jiang Jinyun Jiang 1Xue Long Xue Long 1Nuerziya Yimamu Nuerziya Yimamu 1Kaixin Zhong Kaixin Zhong 1Yingzi Li Yingzi Li 1Xianghuan Cui Xianghuan Cui 1
  • 1 Tongji University, Shanghai, China
  • 2 The First Affiliated Hospital of Naval Medical University,, Shanghai, China

The final, formatted version of the article will be published soon.

    Alzheimer's disease (AD) is a complex neurodegenerative disease that affects elderly individuals, characterized by senile plaques formed by extracellular amyloid beta (Aβ). Autophagy dysfunction is a manifestation of protein homeostasis imbalance in patients with AD, but its relationship with Aβ remains unclear. Here, we showed that in Aβ transgenic Caenorhabditis elegans, Aβ activated the TOR pathway and reduced the nuclear entry of HLH-30, leading to autophagy dysfunction characterized by autophagosome accumulation. Then, utilizing RNA-seq, we investigated the regulatory mechanisms by which HLH-30 modulates autophagy in C. elegans. We found that HLH-30 elevated the transcript levels of v-ATPase and cathepsin, thus enhancing lysosomal activity. This led to an increase in autophagic flux, facilitating more pronounced degradation of Aβ. Moreover, HLH-30 reduced the level of ROS induction by Aβ and enhanced the antioxidant stress capacity of the worms through the gsto-1 gene. Additionally, we identified two HLH-30/TFEB activators, saikosaponin B2 and hypericin, that improved autophagic flux, thereby enhancing protein homeostasis in C. elegans.Overall, our findings suggested that HLH-30/TFEB plays a key role in modulating autophagy and can be considered a promising drug target for AD treatments.

    Keywords: HLH-30, Amyloid beta, Autophagy, HLH-30/TFEB activators, Caenorhabditis elegans

    Received: 15 May 2024; Accepted: 16 Aug 2024.

    Copyright: © 2024 Wang, Lin, Zhang, Gao, Zhou, Ma, Jiang, Long, Yimamu, Zhong, Li and Cui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Hongbing Wang, Tongji University, Shanghai, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.